A screening algorithm for HIV-associated neurocognitive disorders

HIV Medicine

Volumn 11, Issue 10, 2010, Pages 642-649

  Cysique, L A ^a   Murray, J M ^a,b   Dunbar, M ^a   Jeyakumar, V ^a   Brew, B J ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

Antiretroviral therapy; Diagnosis algorithm; HIV associated neurocognitive disorder; HIV AIDS; Mathematical model

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ALGORITHM; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; DIAGNOSTIC ACCURACY; FEMALE; HIV ASSOCIATED DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; OUTPATIENT DEPARTMENT; PREDICTION; PRIORITY JOURNAL; SCREENING TEST; SUPPORT VECTOR MACHINE; TREATMENT DURATION;

ADULT; AGE FACTORS; ALGORITHMS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COGNITION DISORDERS; DECISION SUPPORT TECHNIQUES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 77958585127     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00834.x     Document Type: Article

References (38)

1. Nuwer MR, Barkley GL, Esper GJ, Donofrio PD, Szaflarski JP, Swift TR. Invited article: the US health care system: Part 2: Proposals for improvement and comparison to other systems. Neurology 2008; 71: 1914-1920.
2. Morgan EE, Woods S, Scott J et al. Predictive validity of demographically-adjusted normative standards for the HIV dementia scale. J Clin Exp Neuropsychol 2008; 30: 83-90.
3. Robertson KR, Smurzynski M, Parsons TD et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21: 1915-1921.
4. McArthur J, McDermott MP, McClernon D et al. Attenuated CNS infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol 2004; 61: 1687-1696.
5. Antinori A, Arendt G, Becker JT et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789-1799.
6. Mayeux R, Stern Y, Tang MX et al. Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment. Neurology 1993; 43: 176-182.
7. Stern Y, McDermott M, Albert S et al. Factors associated with incident human immunodefiency virus-dementia. Arch Neurol 2001; 58: 473-479.
8. Heaton RK, Marcotte TD, Mindt MR et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004; 10: 317-331.
9. Hinkin CH, Hardy DJ, Mason KI et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status and substance. AIDS 2004; 18: S19-S25.
10. Valcour V, Paul R. HIV infection and dementia in older adults. Clin Infect Dis 2006; 42: 1449-1454.
11. Satz P, Morgenstern H, Miller E et al. Low education as a possible risk factor for cognitive abnormalities in HIV-1: finding from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 1993; 6: 503-511.
12. Sacktor N, Skolasky RL, Tarwater PM et al. Response to systemic HIV viral load suppression correlates with psychomotor speed performance. Neurology 2003; 61: 567-569.
13. Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 2006; 66: 1447-1450.
14. McArthur JC, Hoover DR, Bacellar H. Dementia in AIDS patients: incidence and risk factors. Neurology 1993; 43: 2245-2252.
15. Bhaskaran K, Mussini C, Antinori A et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008; 63: 213-221.
16. Letendre S, Marquie-Beck J, Capparelli E et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65-70.
17. Cole MA, Margolick JB, Cox C et al. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology 2007; 69: 2213-2220.
18. Ben-Hur A, Ong CS, Sonnenburg S, Scholkopf B, Ratsch G. Support vector machines and kernels for computational biology. PLoS Comput Biol 2008; 4: e1000173.
19. Alladi SM, P SS, Ravi V, Murthy US. Colon cancer prediction with genetic profiles using intelligent techniques. Bioinformation 2008; 3: 130-133.
20. Pino-Mejias RM, Carrasco-Mairena A, Pascual-Acosta MD, Cubiles-De-La-Vega MD, Munoz-Garcia J. A comparison of classification models to identify the Fragile X Syndrome. J Appl Stat 2008; 35: 233-244.
21. Verplancke T, Van Looy S, Benoit D et al. Support vector machine versus logistic regression modeling for prediction of hospital mortality in critically ill patients with haematological malignancies. BMC Med Inform Decis Mak 2008; 8: 56.
22. Cysique L, Maruff P, Brew B. Prevalence and pattern of neuropsychological impairment in HIV/AIDS-infection across pre and post-Highly Active Antiretroviral Therapy eras: a combined study of 2 cohorts. J Neurovirol 2004; 10: 350-357.
23. Howell D. Statistical Methods for Psychology, 5th ed. Pacific Grove, CA: Thomson Learning, 2002.
24. Lovibond SH, Lovibond PF. Manual for the Depression Anxiety Stress Scales, 2nd ed. Sydney: Psychology Foundation, 1995.
25. Grunseit AC, Perdices M, Dunbar N, Cooper DA. Neuropsychological function in asymptomatic HIV-1 infection: methodological issues. J Clin Exp Neuropsychol 1994; 16: 898-910.
26. Mangasarian OL, Musicant DR. LSVM Software: Active Set Support Vector Machine Classification Software. Vol. 2009, 2000. Available at (accessed May 2008).
27. Dunbar M, Murray JM, Cysique LA, Brew BJ, Jeyakumar V. Simultaneous Classification and Feature Selection via Convex Quadratic Minimization with Non-Negativity Constraints. European Journal of Operational Research (submitted).
28. Davis H, Skolasky RJ, Selnes O, Burgess D, McArthur J. Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read 2002; 12: 32-33.
29. Carey C, Woods S, Rippeth J et al. Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol 2004; 18: 234-248.
30. Gonzalez R, Heaton RK, Moore DJ et al. Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. J Int Neuropsychol Soc 2003; 9: 64-71.
31. Cysique LA, Maruff P, Darby D, Brew BJ. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol 2006; 21(2): 185-194.
32. Levine AJ, Hinkin CH, Ando K et al. An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults. J Clin Exp Neuropsychol 2008; 8: 1-8.
33. Cysique LA, Vaida F, Letendre S et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009; 73: 342-348.
34. Cysique LA, Brew BJ. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev 2009; 19: 169-185.
35. Goggin KJ, Zisook S, Heaton RK et al. Neuropsychological performance of HIV-1 infected men with major depression. J Int Neuropsychol Soc 1997; 3: 457-464.
36. Cysique LA, Deutsch R, Atkinson JH et al. Incident major depression does not affect neuropsychological functioning in HIV-infected men. J Int Neuropsychol Soc 2007; 13: 1-11.
37. Sevigny JJ, Albert SM, McDermott MP et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004; 63: 2084-2090.
38. Chadborn TR, Baster K, Delpech VC et al. No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). AIDS 2005; 19: 513-520.